Ivy Brain Tumor Center Opens New Clinical Trial for Patients with Recurrent Grade IV Gliomas

By
Justin.choi
-
0
45
The Ivy Brain Tumor Center at Barrow Neurological Institute announced the opening of a new Phase 0/Ib clinical trial to evaluate AZD1390, an Ataxia telangiectasia mutant kinase inhibitor being developed by AstraZeneca, in patients with recurrent grade IV gliomas.
[The Ivy Brain Tumor Center]

Sorry, but the selected Zotpress account can't be found.

Press Release